Sangamo Therapeutics Inc (SGMO)
0.5558
+0.03
(+6.48%)
USD |
NASDAQ |
May 03, 16:00
0.553
0.00 (0.00%)
After-Hours: 20:00
Sangamo Therapeutics Enterprise Value: 18.43M for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 03, 2024 | 18.43M |
May 02, 2024 | 12.39M |
May 01, 2024 | 16.29M |
April 30, 2024 | 11.12M |
April 29, 2024 | 12.44M |
April 26, 2024 | 11.64M |
April 25, 2024 | 8.988M |
April 24, 2024 | 7.199M |
April 23, 2024 | 12.19M |
April 22, 2024 | 10.26M |
April 19, 2024 | 10.51M |
April 18, 2024 | 5.786M |
April 17, 2024 | 11.31M |
April 16, 2024 | 15.97M |
April 15, 2024 | 18.31M |
April 12, 2024 | 16.22M |
April 11, 2024 | 16.54M |
April 10, 2024 | 12.74M |
April 09, 2024 | 19.62M |
April 08, 2024 | 20.15M |
April 05, 2024 | 19.40M |
April 04, 2024 | 21.82M |
April 03, 2024 | 28.13M |
April 02, 2024 | 23.01M |
April 01, 2024 | 27.70M |
Date | Value |
---|---|
March 28, 2024 | 38.90M |
March 27, 2024 | 30.76M |
March 26, 2024 | 26.95M |
March 25, 2024 | 33.80M |
March 22, 2024 | 44.77M |
March 21, 2024 | 92.59M |
March 20, 2024 | 65.00M |
March 19, 2024 | 56.76M |
March 18, 2024 | 71.25M |
March 15, 2024 | 58.54M |
March 14, 2024 | 58.54M |
March 13, 2024 | 59.46M |
March 12, 2024 | 73.05M |
March 11, 2024 | 76.86M |
March 08, 2024 | 81.11M |
March 07, 2024 | 82.76M |
March 06, 2024 | 98.91M |
March 05, 2024 | 102.48M |
March 04, 2024 | 100.69M |
March 01, 2024 | 116.73M |
February 29, 2024 | 125.63M |
February 28, 2024 | 109.60M |
February 27, 2024 | 120.29M |
February 26, 2024 | 118.51M |
February 23, 2024 | 120.29M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-79.42M
Minimum
Nov 10 2023
1.922B
Maximum
Dec 23 2020
563.30M
Average
585.44M
Median
Oct 09 2019
Enterprise Value Benchmarks
AIM ImmunoTech Inc | 7.819M |
Perspective Therapeutics Inc | 1.055B |
Protalix BioTherapeutics Inc | 58.97M |
Electromed Inc | 148.76M |
Armata Pharmaceuticals Inc | 158.79M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -60.30M |
Revenue (Quarterly) | 2.042M |
Total Expenses (Quarterly) | 63.80M |
EPS Diluted (Quarterly) | -0.34 |
Profit Margin (Quarterly) | -2.95K% |
Earnings Yield | -264.5% |
Normalized Earnings Yield | -116.28 |